Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Disruptive analytics’ Substack by Magnus Ofstad. In this ...

In an interview on CNBC’s Mad Money, Robert Davis said Merck’s (MRK) current pipeline is the most diversified it has been in recent history.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (c), Merck & Co., ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Merck CEO Rob Davis told CNBC’s Jim Cramer that there’s more to the pharmaceutical giant than its lucrative cancer drug, ...

BMO Capital analyst Evan Seigerman has maintained their neutral stance on MRK stock, giving a Hold rating on January 10.Stay Ahead of the ...

Merck's human papillomavirus vaccine has been approved for men in China, it said on Wednesday, providing the U.S. drugmaker a ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Merck accelerates subcutaneous Keytruda rollout to protect cancer drug's dominance as IV patent nears 2028 expiry.